Abstract
ABSTRACT Objectives This study aimed to examine the relationship between the McCance Brain Care Score (BCS) and mortality in the general population. Methods We conducted a prospective, population‐based cohort study using data from the UK Biobank. Participants with complete data enabling calculation of BCS and full mortality information were included. For the longitudinal component, participants without follow‐up BCS data were excluded. Mortality information was obtained via the National Health Service (NHS) Information Centre (England and Wales) and the NHS Central Register Scotland, with follow‐up through December 31, 2022. Results A total of 331,894 participants were included (mean age 56.46 ± 8.07 years; 54.2% women; 91.8% White). Over a median follow‐up of 13.83 years (IQR 13.11–14.55), 27,446 deaths (8.27%) occurred. Higher baseline BCS was significantly associated with lower all‐cause mortality. As a continuous variable, each 1‐point increase in BCS corresponded to a 6% lower risk of death (fully adjusted HR = 0.94; 95% CI 0.94–0.95; p < 0.001). When analyzed in 5‐point increments, participants with BCS 5–10, 10–15, and ≥ 15 had 40%, 53%, and 55% lower mortality risks, respectively, compared with the reference group (BCS < 5) (all p < 0.001; p for trend < 0.001). Cause‐specific analyses revealed inverse associations between BCS and death from malignant neoplasm (HR = 0.95; 95% CI 0.94–0.95), heart disease (HR = 0.90; 95% CI 0.89–0.92), cerebrovascular disease (HR = 0.96; 95% CI 0.94–0.98), respiratory disease (HR = 0.92; 95% CI 0.90–0.94), and diabetes (HR = 0.90; 95% CI 0.84–0.96) (all p ≤ 0.001). In longitudinal analyses of 7114 participants with repeated BCS measurements over a median 4.52 years, persistently high BCS was associated with a 50% lower mortality risk compared with persistently low BCS (HR = 0.50; 95% CI 0.29–0.87). Interpretation These findings suggest that BCS is a practical tool reflecting healthy lifestyle behaviors and clinical measures, aiding early identification of individuals at high risk of mortality and showing promise in health management. Further studies are needed to explore its mechanisms and confirm causality.
Affiliated Institutions
Related Publications
Outcome Predictors of Pneumonia in Elderly Patients: Importance of Functional Assessment
Objectives: To evaluate the outcome of elderly patients with community‐acquired pneumonia (CAP) seen at an acute‐care hospital, analyzing the importance of CAP severity, functio...
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF det...
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world, strongly associated with insulin resistance and the metabolic syndrome. Nonalcoho...
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
OBJECTIVE To assess in diabetic patients with coronary heart disease (CHD) the effect of cholesterol lowering with simvastatin on mortality and the risk of CHD and other atheros...
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Results of previous randomised trials have shown that interventions that lower LDL cholesterol concentrations can significantly reduce the incidence of coronary heart disease (C...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1002/acn3.70256